|Bid||9.60 x 900|
|Ask||10.40 x 1000|
|Day's Range||9.82 - 10.34|
|52 Week Range||8.61 - 19.90|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||20.00|
Legion Partners Asset Management revealed ownership of 3,567,946 shares of the purified-water retailer, equal to 9.1% of the publicly traded stock. On Sept. 17, Legion Partners issued a press release in conjunction with a public letter to shareholders conveying its displeasure with what Legion Partners believes to be the board’s insufficient oversight that has led to the stock’s recent underperformance. Legion Partners feels that a complete “board refresh” is needed to improve corporate independence and governance, and to eliminate long-serving directors whose complacency has “failed to hold management accountable” for poor operational performance.
SOUTH SAN FRANCISCO, Calif. , Sept. 17, 2019 /PRNewswire/ -- Satsuma Pharmaceuticals, Inc. ("Satsuma" or the "Company") (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing ...
Internet services company Cloudflare was set to begin trading Friday, after raising $525 million with an initial public offering that priced Thursday. Cloudflare offered 35 million shares.
SOUTH SAN FRANCISCO, Calif. , Sept. 12, 2019 /PRNewswire/ -- Satsuma Pharmaceuticals, Inc. ("Satsuma" or the "Company") (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing ...
South San Francisco-based Satsuma Pharmaceuticals, Inc. has filed for an IPO of 5 million shares of its common stock. The company said in the filing that some of its existing investors affiliated with some of its directors have expressed interest in buying about $25 million in shares. Founded in June 2016, Satsuma is a clinical-stage biopharma company developing a novel therapeutic product for the acute treatment of migraines.
SOUTH SAN FRANCISCO, Calif., Sept. 3, 2019 /PRNewswire/ -- Satsuma Pharmaceuticals, Inc. ("Satsuma"), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder) for the acute treatment of migraine, today announced that it has commenced an underwritten initial public offering of up to 5,000,000 shares of its common stock. All of the shares to be sold in the offering will be offered by Satsuma. In addition, Satsuma expects to grant the underwriters for the offering a 30-day option to purchase up to an additional 750,000 shares of common stock at the public offering price, less underwriting discounts and commissions.